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be the key of any strategies designed to reduce the risk of MRSA acquisition by
patients with CF.
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In the Umbria Region the CF newborn screening (NBS) was carried out since
the year 2000. The tests were run in the “CRI Laboratory” in Rome using the
IRT1/OLA31/IRT2 protocol [1]. For all positive subjects more detailed tests were
suggested in order (a) to ﬁnd mutations not contained in the OLA31 panel, (b) to
study the available family members to ﬁnd CF traits and at risk couples. The whole
CF gene was studied by DGGE analysis and by sequencing in patients with positive
or borderline sweat test. In the 7 years 15 CF patients out of 50,941 newborns were
found (1:3465), 8 with the classic and 7 with the mild form. The IRT1 and OLA
positive cases for at least one mutation or IRT2 positive cases identiﬁed were 114:
79 (69%) of them did not come to our observation. Of the 35 examined subjects 13
were found to be CF affected (6 classic and 7 mild) and 22 were heterozygotes. In
6 (4 classic and 2 mild) out of 13 CF patients the genotype was already known by
the OLA panel while in 5 CF patients (1 classic and 4 mild) only one mutation was
detected and in 2 CF patients (1 classic and 1 mild) the OLA panel was negative. The
other 2 patients had a clinical diagnosis as the IRT test was negative: they showed
a classic CF and the diagnosis was conﬁrmed by sweat test and identiﬁcation of
the CFTR gene mutations. The IRT assay, even with the 63% of false positive
results, was very useful in the identiﬁcation of the CFTR gene mutations in both
the homozygous and heterozygous subjects. In our experience the IRT positive cases
gave us the possibility to perform the appropriate genetic counselling followed by
the cascade screening and 6 new at risk couples and 2 atypical CF were detected. On
the contrary the IRT test failed to detect 2 out of 8 classical CF and the OLA in our
population was able to ﬁnd 65.38% of the mutations (17 out of 26) in 13 patients
with the IRT positive test. Our data suggest that the NBS for CF has a great poten-
tiality in the prospective prevention by means of the genetic counselling followed by
cascade screening. The need exists for a better knowledge of the prevention power of
the NBS program by the medical staff and by the families of the screened subjects.
Even if in the last few years the number of the people coming to have more detailed
genetic analysis after a positive NBS test is increasing, we think that more attention
has to be spent to suggest further investigation for the maximum preventive effect.
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The most widespread strategy of neonatal screening for CF consists in the mea-
surement of immunoreactive trypsinogen (IRT) from dried blood spots coupled
with CFTR mutation analysis. However, this strategy is complicated by the high
cost of DNA analysis, the need for an informed consent and of genetic counselling.
Moreover, the false positive rate of the IRT assay is quite high (1−2%) resulting in
too many unnecessary DNA tests. Thus, alternative markers are being investigated
to avoid these drawbacks. Pancreatitis-associated protein (PAP) is a stress protein
synthesized by the diseased pancreas, shown to be elevated in newborns with CF
and potentially useful in combination with IRT to ameliorate speciﬁcity of the
screening strategy. On these bases, a multi-center feasibility study including two
sites in USA, one in Germany and one in Italy has been performed with the aim
to assess the usefulness of the combined IRT-PAP CF protocol against the more
traditional IRT/CFTR strategy. Measurement of IRT and PAP was performed in
n=18080 neonates. IRT was detected by a time resolved ﬂuoroimmunoassay (Perkin-
Elmer Life Sciences, Turku, Finland) in dried blood spots collected at age 3−5 days.
PAP was tested by a novel two site-ﬂuoroimmunometric assay provided by Perkin-
Elmer. Based on the calculation of the percentiles of data obtained in the different
centres, hypothetical cut-offs were set at IRT>50 ng/mL and PAP >1.8 ng/mL
or IRT>100 ng/mL and PAP>1.0 ng/mL. IRT/PAP strategy may be a promising
alternative since it could decrease the number of mutation analysis required (down
to 0.3%) thereby decreasing the cost of the screening as well as the number of
carriers identiﬁed. Limitations of this study include the rather small sample size
that does not allow the evaluation of the sensitivity in detecting mild CF forms.
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Aim: Nebulization of inhaled drugs has improved in the past years thanks to the
development of a new generation of nebulizers, characterized by greater efﬁciency,
portability and shorter nebulization times. These achievements in aerosol delivery
may improve quality of life and adherence to therapy in cystic ﬁbrosis (CF) patients.
The aim of this study was to compare in vitro performance of four devices [PARI
TurboBOY N LC PLUS (LC), PARI eFlow Rapid (eF), Optineb-ir (Op) and Akita
LC Star (Ak)] when nebulizing 4 ml of Bramitob®, a new formulation of inhaled
tobramycin developed by Chiesi Farmaceutici.
Methods: By means of a Next Generation Impactor, the aerodynamic particle
size distribution was studied evaluating the mass median aerodynamic diameter
(MMAD) and ﬁne particle fraction (FPF). Moreover, the Delivered Dose (DD) and
the duration of nebulization were measured.
Results: The MMAD was lowest with Ak, whereas higher with eF, LC and Op
(2.7mm, 4.1, 4.8 and 5.5mm respectively). The FPF was higher with Ak and eF
(77.3 and 66mg) and lower with LC and Op (50.4 and 44.2mg). The DD was
similar with eF, LC and Op (86, 81.6 and 87.9mg) but was much higher with Ak
(147.2mg). Nebulization time was lowest with eF (5.5min) followed by LC and
Op (7.4 and 9.9min respectively), whereas much longer with Ak (24.3min).
Conclusions: Optineb-ir and eFlow Rapid are characterized by an aerodynamic
particle size distribution and a delivered dose similar to that of PARI TurboBOY N
LC PLUS, which is the device used in the clinical trials conducted with Bramitob®.
However, small differences, such as those observed in the nebulization time, may
represent an important feature when considered in the daily therapies that CF
patients undergo.
